tbuckley/cabot-search huggingface dataset:
New Safety Standard for Medical Device Wires Proposed
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Clinical Immunology, Biotherapy and Chemotherapy in the Diagnosis, Prevention and Treatment of Disease . By John A. Kolmer, M.D., and Louis Tuft, M.D. 8°, cloth, 941 pp., with 27 illustrations, including 11 color plates. Philadelphia: W. B. Saunders Company, 1941. $10.00.
Journal: New England Journal of Medicine (1942)
Comparison between Carcinogenicity and Mutagenicity Based on Chemicals Evaluated in the IARC Monographs
Authors: H. Bartsch, L. Tomatis
Journal: Environmental Health Perspectives (1983)

The qualitative relationship between carcinogenicity and mutagenicity (DNA-damaging activity), based on chemicals which are known to be or suspected of being carcinogenic to man and/or to experimental animals, is analyzed using 532 chemicals evaluated in Volumes 1-25 of the IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. About 40 compounds (industrial processes) were found to be either definitely or probably carcinogenic to man, and 130 chemicals have been adequately tested in rodents and most of them also in various short-term assays. For a comparison between the carcinogenicity of a chemical and its behavior in short-term tests, systems were selected that have a value for predicting carcinogenicity. These were divided into mutagenicity in (A) the S. typhimurium/microsome assay, (B) other submammalian systems and (C) cultured mammalian cells; (D) chromosomal abnormalities in mammalian cells; (E) DNA damage and repair; (F) cell transformation (or altered growth properties) in vitro. The following conclusions can be drawn. In the absence of studies in man, long-term animal tests are still today the only ones capable of providing evidence of the carcinogenic effect of a chemical. The development and application of an appropriate combination of short-term tests (despite current limitations) can significantly contribute to the prediction/confirmation of the carcinogenic effects of chemicals in animals/man. Confidence in positive tests results is increased when they are confirmed in multiple short-term tests using nonrepetitive end points and different activation systems. Assays to detect carcinogens which do not act via electrophiles (promoters) need to be developed. The results of a given short-term test should be interpreted in the context of other toxicological data. Increasing demand for quantitative carcinogenicity data requires further examination of whether or not there is a quantitative relationship between the potency of a carcinogen in experimental animals/man, and its genotoxic activity in short-term tests. At present, such a relationship is not sufficiently established for it to be used for the prediction of the carcinogenic potency of new compounds.
Genetic Regulation of Mammary Carcinogenesis in the Rat by Susceptibility and Suppressor Genes
Authors: Michael N. Gould, Rong Zhang
Journal: Environmental Health Perspectives (1991)

Rat strains differ in their susceptibilities to mammary carcinogenesis. Strains such as Wistar-Furth are very susceptible to chemically induced carcinogenesis. This phenotype is controlled by autosomally dominant susceptibility genes. Strains such as the Copenhagen are resistant to spontaneous and induced mammary carcinogenesis. This phenotype is controlled by an autosomal dominant gene termed the mammary carcinoma suppressor (MCS). Strains with intermediate susceptibility such as the F344 carry neither the MCS nor susceptibility genes. Both the MCS and susceptibility genes are chiefly active within the mammary parenchyma. Both genes act at carcinogenesis stages beyond carcinogen metabolism and DNA adduction. The MCS gene completely inhibits both palpable and microcarcinomas. It does not inhibit focal alveolar hyperplasias. Its gene product acts solely within the mammary epithelial cell in which it is produced. We are currently investigating the interactions of various oncogenes and the MCS gene. In addition, efforts are underway to identify and clone this gene.
Minor Comments
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radiation accidents and the role of the physician: a post-Chernobyl perspective
Authors: G. K. MacLeod
Journal: JAMA (1986)

No longer can it be said that no one has died from radiation in a nuclear power plant. Until the Chernobyl accident, the nuclear power industry had an enviable health record compared with that of oil-fed or coal-fired power plants that generate electricity. However, the Three Mile Island (TMI) accident in 1979 was a warning shot across the bow of the nuclear industry. This April, a direct hit occurred at Chernobyl. What have we learned in the seven years between these accidents? What have we done to improve the management and reduce the risk of a radiation accident at a nuclear power plant? What efforts have we made to educate ourselves and the public about the likelihood of nuclear incidents and accidents, and to minimize their health effects? Has activist sentiment against nuclear power perhaps been so strident that nuclear advocates have been coerced into defensively denying that any health
Editorial Board
Authors: Donald Leung, Stanley Szefler, Colo Associate, Cezmi Akdis, Davos Switzerland, Andrea Apter, Pedro Philadelphia, Chicago Avila, Joshua Boyce, Robert Bush, Fred Finkelman, Cincinnati Ohio, Dennis Ledford, Tampa Fla, Deborah Meyers, Luigi Notarangelo, David Peden, Chapel Hill, Harald Renz, Marburg Germany, Marc Rothenberg, Hirohisa Saito, William Shearer, Scott Sicherer, New York, Erika Von Mutius, Germany Munich, Vernon Statistics Editor, Hershey Chinchilli, Gordon Bloomberg, St Louis, Larry Borish, Angela Haczku, Jordan Orange, Darryl Zeldin, Leonard Bacharier, Sten Dreborg
Journal: Journal of Allergy and Clinical Immunology (2014)
Mortality in relation to smoking
Authors: J Johnson, J Lyndon, J Crofts, G Thonet, S Fletcher, P May, A Piers, A Brain, P Packer, Janet Porter, D Reilly, A Allan, A Goudarzi-Langroudi, J Scoble, Judith Digby, Medea Frangoulis, V Moshakis, D Vellacott, R Cox, A Klidiian, E Thomas, J Evans, P Felton, C Bartolo, R Stewart, S Patel, G Guindi, M Sankarankutty, P Ward, J Al-Sheikhli, C Apap-Bologna, Hefny Taha, P Jana, A Majumder, S Ghosh, H Bodle, P Kakrania, A Mathur, P Paine, R Chaudhuri, A Hassan, M Dias, S Kasinathan, Y F-E Shafiq, G Shehata, S Al-Tikriti, El Mekki, M Sarsam, W Smith, G Zayed, H Adhikary, Y Leong, M Quinlan, K Al-Hasso, A Bhave, D Elder, J Forbes, A Haque, R Harisha, M Hulse, P Kelly, M Moalypour, A Osung, Y Wijayanayagam, A Dissanayaka, M Flaim, I Gillespie, A Hameed, J Hammond-Evans, M Holloway, M Johnson, J Knott, J Mullanv, S Nouri, K Rogers, J Slack, S Al-Habbal, S Al-Wattar, I Evbuomwan, G Gibson, A Heath, F Hughes, I Learmonth, Roxane Mckay, Y Milne, U Nair, B Packard, H Refai, R Waldes, Abdel Hadi, Agius Bristol, J Carr, P Chilton, R Gourdie, M James, R Jury, J Kundu, M Lavelle, H Low, B St, C Lucas, N Matthews, J Mosley, S Nyaho, W Paterson, J Pooley, D Ranasinghe, Yvonne Schwartz, M Sibley, V Walsh, G Williams, R Williams, M Younis, R Allum, T Archer, C Arciszewski, A Ball, J Bonkowski, T Day, P De Boer, P Dias, Kay Evans, L Gilliland, J Grattage, M Greenall, R Ham, G S M Harrison, J Hyland, J Ingoldby, M Jamison, A Johns, Linda Jones, T-K Khoo, M Lewis, E Minchin, T Moore, B Noble, A Pattison, H Redford, D Rennie, K Rolles, W Scott, J Scurr, J Stilwell, J Thorpe, J Tresadern, A Tucker, L Welsh, E Evans, K Fananapazir
Journal: BMJ (1977)
A Novel but Potentially Risky Therapy for Severe Rheumatoid Arthritis
Journal: Annals of Internal Medicine (1999)

Summaries for Patients5 October 1999A Novel but Potentially Risky Therapy for Severe Rheumatoid ArthritisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-7-199910050-00044 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Rheumatoid arthritis is a form of autoimmune arthritis. Autoimmune means that the disease results when a person develops immune reactions against substances in his or her own body. Rheumatoid arthritis can be disabling and difficult to treat. Some researchers think it might make sense to treat autoimmune diseases with strong drugs to wipe out the abnormal immune cells (chemotherapy), followed by replacement of the abnormal blood cells with early forms of normal ones (stem-cell transplantation). The normal stem cells in this study come from a person who does ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “High-Dose Chemotherapy and Syngeneic Hemopoietic Stem-Cell Transplantation for Severe, Seronegative Rheumatoid Arthritis.” It is in the 5 October 1999 issue of Annals of Internal Medicine (volume 131, pages 507-509). The authors are G. McColl, H. Kohsaka, J. Szer, and I. Wicks.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHigh-Dose Chemotherapy and Syngeneic Hemopoietic Stem-Cell Transplantation for Severe, Seronegative Rheumatoid Arthritis Geoff McColl , Hitoshi Kohsaka , Jeff Szer , and Ian Wicks Metrics 5 October 1999Volume 131, Issue 7Page: 507KeywordsAutoimmune diseasesBlood cellsCancer treatmentCellsChemotherapyDrugsRheumatoid arthritisStem cellsTransplantationTwins ePublished: 15 August 2000 Issue Published: 5 October 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.Loading ...
Health, Speech and Song. A Practical Guide to Voice-Production.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Crossing the divide from vaccine technology to vaccine delivery. The critical role of providers
Authors: W. A. Orenstein
Journal: JAMA (1994)

On May 14, 1796, Edward Jenner performed the first successful vaccination against smallpox with virus obtained from a woman infected with cowpox. In the almost 200 years since that sentinel event, smallpox has been eradicated and polio has been eliminated from the Americas. Sophisticated biotechnology has brought us hepatitis B vaccine, the first licensed vaccine developed using recombinant DNA techniques. New technology has permitted linkage of<i>Haemophilus influenzae</i>type b capsular polysaccharide to protein carriers to improve the immune response of infants, and<i>H influenzae</i>type b invasive disease has been reduced by more than 95% in the 5 years since introduction of the first conjugate vaccines.<sup>1</sup>As reported by Granoff et al<sup>2</sup>in this issue ofThe JOURNAL, research continues into improving the already excellent immune response to these conjugate vaccines. While much more remains to be done in developing new and improved vaccines, the system of
Recall of Isoniazid Used for Antimicrobial Susceptibility Testing for Tuberculosis
Journal: JAMA (2000)

Becton Dickinson Biosciences (Sparks, Maryland) has issued a voluntary recall of a lot of isoniazid [INH] (drug lot no. 9335260) used for antimicrobial susceptibility testing (AST) of Mycobacterium tuberculosis. The recalled INH lot was sold as components of BACTEC S.I.R.E. kits (lot nos. 9327296, 9342298, and 9327298) and as individual drug for reconstitution (BACTEC Isoniazid kit lot no. 9327297) during January 2000-August 25, 2000.
National Health Service
Authors: W. M. Christie
Journal: BMJ (1948)

<h3>Introduction</h3> Health system responses to the emergence of non-communicable diseases (NCDs) in many Southeast Asian nations, Cambodia included, have been insufficient. Little is known about how people suffering from such conditions behave in constrained contexts. We examined the experience of patients with NCDs as they seek care for their conditions and manage them. <h3>Methods</h3> In-depth interviews with 28 purposively selected patients with hypertension and/or diabetes using an interview guide to capture the trajectory followed by interviewees from the development and recognition of symptoms to adherence to treatment. A general outline of major topics to be discussed was used instead of a predetermined list of specific questions. <h3>Results</h3> All interviewees had experienced symptoms for a substantial period of time, sometimes many years, before being diagnosed. Initial treatment focused on symptoms instead of underlying conditions, often at considerable financial cost. Following diagnosis, many struggled to take medicines daily for their condition and adhering to the required behaviour changes. Many resorted to complementary medicine. Lack of financial resources was a common reason to discontinue treatment. Many reported loss of income and assets such as livestock and productive land and increasingly relied on others. <h3>Conclusion</h3> In order to assist people with NCDs in Cambodia, there is a need for a multipronged approach focusing on communities and healthcare providers. Information campaigns could focus on the timely recognition by communities of symptoms indicative of the conditions, together with instigating demand for routine screening at qualified health providers. Peer support is considerable, and locally adjusted approaches based on this principle should be considered.
National policy, attitudes undergo some changes in regard to drinking
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of circulating microRNAs predictive of HCC in DAA-cured HCV-related cirrhosis
Authors: marie-laure plissonnier, Alessandro Loglio, Francesca Guerrieri, Floriana Facchetti, Claude Caron de Fromentel, Mirjam Zeisel, Pietro Lampertico, Massimo Levrero
Journal: Journal of Hepatology (2020)
Phytosterolemia
Authors: Barbara J. Bain, Subarna Chakravorty
Journal: American Journal of Hematology (2016)

Phytosterolemia is an autosomal recessive condition resulting from mutation in either the ABCG5 or the ABCG8 gene, in which there is excessive absorption of dietary sterols including plant sterols. As a result there is formation of xanthomas and premature atherosclerosis. The condition appears to be rare but it is likely that it is underdiagnosed. Examination of a blood film, with recognition of the significance of the particular combination of large platelets and stomatocytosis, is critical in making the diagnosis. Often the platelet count is reduced. Diagnosis is important because of the premature vascular disease and because patients who are misdiagnosed have sometimes been treated with corticosteroids or splenectomy 1. Correct diagnosis has become particularly important with the availability of specific treatment.
Editorial: Surgery of hemiplegia.
Journal: BMJ (1974)

the intake of pyridoxine.Patients previously unable to tolerate levodopa because of nausea and vomiting can achieve adequate dosage with the combination, though in other dopa-tolerant patients the optimum response to combined treatment is no greater than to dopa alone.The central side effects of dopa are not altered by combined therapy, and dose-limiting involuntary movements occur at the same plasma dopa levels, the incidence of neuropsychiatric disorders is similar, and possibly there may be problems with the on-off effect earlier in the course of combined treatment.This effect is the abrupt onset of akinesia followed by the equally sudden return of the therapeutic response to levodopa; it may occur in up to 50%0 of patients after several years of treatment on levodopa alone.At present only a single fixed ratio of dopa to decarboxylase inhibitor is available, and patients who take a low dopa dosage may not gain any advantages from the combination.Tablets containing 10, 50, and 100 mg of levodopa with a fixed dosage of 25 mg carbidopa should soon be available. 16Treatment of patients still requires considerable judgement by the physician in balancing the therapeutic and side effects of the different antiparkinsonian drugs, and unfortunately no treatment available at present halts the progression of Parkinson's disease.
Secretary of Health, Human Services to hear recommendations for improving immunization
Authors: C. Marwick
Journal: JAMA (1990)

TODAY'S MEASLES outbreaks may be the first sign of serious trouble in the nation's immunization system. Partly because rubeola is more readily transmitted than other childhood infections such as rubella and mumps, "the appearance of measles is a sensitive indicator of the inadequacies of our vaccination system," says Donald A. Henderson, MD, Johns Hopkins University School of Public Health, Baltimore, Md, and chair of the National Vaccine Advisory Committee to the secretary of the US Department of Health and Human Services. "It raises the specter of whether we might expect, further down the line, outbreaks of polio [should it be imported], pertussis, and diphtheria." If the system is failing to provide the current vaccines——such as for measles—to the nation's children effectively, then it is totally inadequate to provide the new vaccines that are waiting in the wings, Henderson says. The latter include<i>Haemophilus influenzae</i>vaccines for 2-month-old infants (<i>JAMA</i>. 1990;264:1375)
How white and African Americans view their health and social problems. Different experiences, different expectations
Authors: R. J. Blendon
Journal: JAMA (1995)

DESPITE increases in expenditures and expansions of many US health and social welfare programs and institutions, racial disparities persist in many aspects of American society. Particularly troubling is the reality that the health of our nation's population differs so greatly by race. A number of studies in recent years have documented substantial differences between white and African Americans in health status, morbidity and mortality, access to health services, and perceptions of quality in health care services received.<sup>1-9</sup> Consistent with these reports of differences in overall health, national opinion surveys show that African Americans are more likely than whites to rate the health services in their communities as fair or poor (46% and 23%)<sup>10</sup>; our study also indicates that African Americans are more likely to state that the health system in this country needs to be completely rebuilt (42% vs 31%). This disparity between the assessments of African Americans